Beeline Medicines presented the detailed results of its Phase 2 trial of afimetoran in systemic lupus erythematosus on November 11 at the American College of Rheumatology Convergence meeting in Orlando. Afimetoran, an oral, once-daily inhibitor of Toll-like receptors 7 and 8, was discovered at Bristol Myers Squibb and licensed to Beeline in July 2025. The company had reported in September that the trial met its primary endpoint; the November 11 presentation supplied the full dataset behind that headline.
The study randomized 248 adults with active, moderate-to-severe lupus to afimetoran at 2.5 mg, 10 mg or 30 mg, or to placebo, for 48 weeks on top of standard care with a mandatory steroid taper. At week 48, response on the SLE Responder Index-4 was 67.8 percent, 64.1 percent and 66.1 percent across the three doses, against 34.4 percent on placebo, a placebo-adjusted difference of 30.2 to 31.5 percentage points, with a p-value below 0.001 at every dose. Secondary measures pointed the same way: BICLA response of 38.7 to 50.8 percent against 27.9 percent, lupus low disease activity in 35.6 to 39.1 percent against 21.3 percent, and 71.9 to 75.0 percent of treated patients reaching or holding a steroid dose of 7.5 mg a day or less, against 50.0 percent on placebo.
Safety over 48 weeks was, in the company’s account, unremarkable for an immunomodulator. Overall adverse event rates were 86.6 percent on afimetoran against 79.0 percent on placebo, but severe events were less frequent on the drug, 3.2 percent against 9.7 percent, as were events leading to discontinuation, 3.2 percent against 9.7 percent. Serious infections occurred in 0 to 3.2 percent across doses against 4.8 percent on placebo, and there were no deaths. Biomarker analyses showed rapid suppression of the type I interferon gene score from the first assessment at week 2, sustained to week 48.
Beeline said it will advance afimetoran into Phase 3 development in systemic lupus in 2027. Its pivotal program has already begun in skin-predominant disease: the Phase 2/3 DISCOVERY trial in cutaneous lupus, targeting about 390 participants, is enrolling. Afimetoran holds Food and Drug Administration Fast Track designation for systemic lupus, granted in May 2025, and is not approved in any country.
The readout lands in a lupus field that is suddenly crowded. Biogen’s litifilimab has Phase 3 systemic lupus results due by the end of 2026, and Beeline’s flat dose-response, with the lowest dose performing as well as the highest, gives it room to pick a Phase 3 dose on tolerability rather than efficacy. What the data do not yet show is performance against an active comparator or durability beyond 48 weeks, the two questions the pivotal program will have to answer.